D. Cahill

Rebecca A Betensky, Tracy T Batchelor, Patrick J Codd, 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.

Shawn M. Gillespie, William A. Flavahan, J. Aster, 2017, Cell stem cell.

Microscale dynamics of electrophysiological markers of epilepsy

Mirela V. Simon, E. Halgren, S. Cash, 2020, Clinical Neurophysiology.

The effect of IDH1 mutation on the structural connectome in malignant astrocytoma

Kyle R. Noll, S. Kesler, D. Cahill, 2017, Journal of Neuro-Oncology.

Microscale physiological events on the human cortical surface

Yun Goo Ro, Ziv M. Williams, Seung Woo Lee, 2019, bioRxiv.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Tracy T Batchelor, Thomas Benner, A Gregory Sorensen, 2007, Cancer cell.

Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma

Yuchen Jiao, Bert Vogelstein, Chetan Bettegowda, 2011, Science.

MRS for D-2HG Detection in IDH-Mutant Glioma

D. Cahill, T. Batchelor, O. Andronesi, 2019, Glioma Imaging.

An integrated RF-receive/B0-shim array coil boosts performance of whole-brain MR spectroscopic imaging at 7 T

Jacob K. White, L. Wald, E. Adalsteinsson, 2020, Scientific Reports.

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate

B. Rosen, A. Iafrate, D. Cahill, 2015, Clinical Cancer Research.

Predictors of survival in contemporary practice after initial radiosurgery for brain metastases.

P. Brown, D. Cahill, M. McAleer, 2013, International journal of radiation oncology, biology, physics.

Sporadic multiple meningiomas harbor distinct driver mutations

D. Aust, D. Cahill, P. Brastianos, 2021, Acta neuropathologica communications.

Neurologic complications of melanoma

N. Wang, D. Cahill, P. Brastianos, 2019, Cancer.

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.

P. Brown, M. J. van den Bent, D. Cahill, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined inhibition of KDM6A/B and HDACs exacerbates integrated stress response and mediates therapeutic effects in IDH1-mutant glioma

H. Wakimoto, D. Cahill, A. Cribbs, 2020 .

CELL BIOLOGY AND SIGNALING

V. P. Collins, Michael A. Koldobskiy, R. Spang, 2010 .

Primary and Metastatic Brain Tumors

D. Cahill, J. Loeffler, N. Shonka, 2015 .

Extent of Resection Versus Molecular Classification: What Matters When?

D. Cahill, Victoria E. Clark, 2019, Neurosurgery clinics of North America.

Diagnosis of acute lymphoblastic leukemia from intracerebral hemorrhage and blast crisis. A case report and review of the literature

D. Cahill, B. Nahed, B. Walcott, 2010, Clinical Neurology and Neurosurgery.

Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis

S. Spiegl-Kreinecker, D. Cahill, P. Brastianos, 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

Unusual visual symptoms in a patient with bilateral vertebral artery dissection: a case report.

D. Cahill, W. Koroshetz, J. Nagurney, 2006, The Journal of emergency medicine.

MRS methods used in the literature for detection of D-2 HG in patients with mutant IDH glioma

B. Rosen, A. Sorensen, D. Cahill, 2013 .

A Rapid Genotyping Panel for Detection of Primary Central Nervous System Lymphoma.

Matthew J. Frigault, D. Cahill, B. Nahed, 2021, Blood.

Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop.

Raymond Y Huang, Susan M. Chang, D. Brat, 2019, Neuro-oncology advances.

The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity.

A. Iafrate, H. Wakimoto, D. Cahill, 2017, Cancer research.

Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma

Nicholas D. Camarda, S. Carter, A. Iafrate, 2020, Nature Genetics.

Commentary: The Glioma-Network Interface: A Review of the Relationship Between Glioma Molecular Subtype and Intratumoral Function.

D. Cahill, W. Curry, Bryan D Choi, 2020, Neurosurgery.

Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.

A. Giobbie-Hurder, R. Sullivan, K. Flaherty, 2019, The oncologist.

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

Marcela V Maus, William T Curry, Brian V Nahed, 2019, Nature Biotechnology.

Commentary: Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.

D. Cahill, B. Nahed, W. Curry, 2021, Neurosurgery.

Using Histopathology to Assess the Reliability of Intraoperative Magnetic Resonance Imaging in Guiding Additional Brain Tumor Resection: A Multicenter Study.

Steven R. Abram, G. Sutherland, M. Smyth, 2020, Neurosurgery.

Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery.

Steven R. Abram, G. Sutherland, E. Leuthardt, 2020, Journal of neurosurgery.

Zinc Finger MYND-Type Containing 8 (ZMYND8) is epigenetically regulated in mutant Isocitrate Dehydrogenase 1 (IDH1) glioma to promote radioresistance

R. Tagett, D. Cahill, Maohui Luo, 2022, bioRxiv.

Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells.

H. Wakimoto, D. Cahill, Julie J. Miller, 2020, Cancer discovery.

MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma.

D. Cahill, Julie J. Miller, 2020, Neuro-oncology.

A multi-institutional analysis of factors influencing surgical outcomes for patients with newly diagnosed grade I gliomas.

Steven R. Abram, G. Sutherland, M. Smyth, 2019, World neurosurgery.

A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.

H. Wakimoto, D. Cahill, R. Martuza, 2016, Neuro-oncology.

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.

Tracy T Batchelor, Richard Lugg, Andrew Menzies, 2006, Cancer research.

Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas

H. Wakimoto, D. Cahill, P. Brastianos, 2017, Oncotarget.

The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases

A. Giobbie-Hurder, S. Carter, H. Wakimoto, 2019, Clinical Cancer Research.

Patterns of somatic mutation in human cancer genomes

E. Birney, A. Nicholson, M. Stratton, 2007, Nature.

Factors that modify the risk of intraoperative seizures triggered by electrical stimulation during supratentorial functional mapping

Mirela V. Simon, D. Cahill, B. Nahed, 2019, Clinical Neurophysiology.

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma

Mariella G. Filbin, McKenzie L. Shaw, Lisa Mayr, 2019, Cell.

DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA

R. Deberardinis, K. Ligon, D. Cahill, 2021, bioRxiv.

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis

A. Giobbie-Hurder, S. Carter, D. Cahill, 2021, Nature Communications.

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

Brian L. Shaw, A. Giobbie-Hurder, S. Carter, 2020, Nature Medicine.

Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas.

D. Cahill, K. Jafari-Khouzani, T. Batchelor, 2020, Radiology.

Deep learning super-resolution magnetic resonance spectroscopic imaging of brain metabolism and mutant isocitrate dehydrogenase glioma

D. Cahill, O. Andronesi, U. Neuberger, 2022, Neuro-oncology advances.

Targeting the PI3K/Akt/mTOR-pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.

A. Giobbie-Hurder, S. Carter, H. Wakimoto, 2019, Neuro-oncology.

MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.

A. Giobbie-Hurder, S. Carter, D. Cahill, 2019, Blood advances.

Mutation Screening of the TNFRSF11A Gene Encoding Receptor Activator of NFkB (RANK) in Familial and Sporadic Paget's Disease of Bone and Osteosarcoma

M. Adams, A. Sparks, J. Venter, 2001, Calcified Tissue International.

De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma

R. Deberardinis, K. Ligon, D. Cahill, 2022, Cancer cell.

Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma.

P. Sharp, Monica Stanciu, M. Yaffe, 2017, Cancer cell.

Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord

H. Wakimoto, D. Cahill, P. Brastianos, 2022, Acta Neuropathologica.

Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma

S. Spiegl-Kreinecker, D. Cahill, P. Brastianos, 2021, Neuropathology and applied neurobiology.

Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

Ameya R. Kirtane, H. Wakimoto, D. Cahill, 2020, Cancer Research.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities

P. Wen, D. Cahill, P. Brastianos, 2022, Pigment cell & melanoma research.

Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.

B. Rosen, A. Sorensen, D. Cahill, 2013, The Journal of clinical investigation.

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

Mark D Anderson, Jennie W. Taylor, Mark D. Anderson, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations

Brian L. Shaw, D. Cahill, P. Brastianos, 2019, Cancer.

A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.

D. Cahill, W. Curry, P. Brastianos, 2018, Neurosurgery.

Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations

D. Cahill, W. Curry, P. Brastianos, 2021, Neurologia medico-chirurgica.

Case records of the Massachusetts General Hospital. Case 10-2010. A 37-year-old woman with weakness and a mass in the brain.

D. Cahill, M. Frosch, K. Davis, 2010, The New England journal of medicine.

Verapamil and chlorpromazine inhibit the budding of Sindbis and vesicular stomatitis viruses from infected chicken embryo fibroblasts.

D. Cahill, M. Schlesinger, 1989, Virology.

The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study

D. Cahill, Y. Liu, J. D. de Groot, 2018, Journal of Neuro-Oncology.

Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma

H. Wakimoto, D. Cahill, J. Golfinos, 2018, Clinical Cancer Research.

Blockade of transforming growth factor‐β signaling enhances oncolytic herpes simplex virus efficacy in patient‐derived recurrent glioblastoma models

A. Iafrate, H. Wakimoto, D. Cahill, 2017, International journal of cancer.

From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.

D. Cahill, O. Andronesi, G. Dunn, 2013, Neurosurgical focus.

Mutations of mitotic checkpoint genes in human cancers

Bert Vogelstein, Kenneth W. Kinzler, Christoph Lengauer, 1998, Nature.

Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

Rebecca A Betensky, Matija Snuderl, David N Louis, 2011, Cancer cell.

Accelerated progression of IDH mutant glioma after first recurrence.

D. Cahill, T. Batchelor, Julie J. Miller, 2019, Neuro-oncology.

Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma

Maristela L Onozato, A. Iafrate, K. Flaherty, 2016, Clinical Cancer Research.

Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis

Alyssa R. Richman, Brian L. Shaw, A. Regev, 2021, Cell.

Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy

Maristela L Onozato, A. Iafrate, H. Wakimoto, 2019, Scientific Reports.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

M. Weller, D. Cahill, K. Plate, 2018, Nature Medicine.

Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients

C. Bettegowda, D. Cahill, W. Curry, 2017, Neuro-oncology.

BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology

M. Meyerson, D. Louis, D. Cahill, 2015, Acta Neuropathologica.

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma

H. Wakimoto, D. Cahill, A. Cribbs, 2022, bioRxiv.

Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma

Christian M. Metallo, K. Ligon, B. Bernstein, 2018, Cell.

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

A. Iafrate, P. Wen, D. Cahill, 2018, Nature Communications.

Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas

A. Iafrate, H. Wakimoto, D. Cahill, 2014, Clinical Cancer Research.

Evolution of delayed resistance to immunotherapy in a melanoma responder

M. Nowak, E. Ruppin, P. Sorger, 2021, Nature Medicine.

Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic

H. Wakimoto, D. Cahill, P. Brastianos, 2020, Acta neuropathologica communications.

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas

K. Aldape, M. Gilbert, D. Cahill, 2015, Acta Neuropathologica.

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?

Jennifer S. Yu, J. Buckner, D. Cahill, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma

A. Iafrate, D. Louis, D. Cahill, 2019, Acta neuropathologica communications.

Three classes of genes mutated in colorectal cancers with chromosomal instability.

J. Ptak, K. Kinzler, B. Vogelstein, 2004, Cancer research.

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas

M. Meyerson, R. Beroukhim, S. Carter, 2016, Neuro-oncology.

Microenvironmental correlates of immune checkpoint inhibitor response in human melanoma brain metastases revealed by T cell receptor and single-cell RNA sequencing

McKenzie L. Shaw, Brian L. Shaw, S. Carter, 2021, bioRxiv.

Sporadic hemangioblastomas are characterized by cryptic VHL inactivation

K. Cibulskis, G. Getz, M. Meyerson, 2014, Acta neuropathologica communications.

Origin of Gliomas

D. Cahill, Ş. Turcan, Şevin Turcan, 2018, Seminars in Neurology.

Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

Ameya R. Kirtane, H. Wakimoto, D. Cahill, 2021, Cancer Research.

Mutant IDH Inhibitors Induce Lineage Differentiation in IDH-mutant Oligodendroglioma

K. Ligon, I. Tirosh, H. Wakimoto, 2021, medRxiv.

PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors

A. Iafrate, H. Wakimoto, D. Cahill, 2019, Clinical Cancer Research.

Molecular pathogenesis and therapeutic implications in pediatric high‐grade gliomas

Mariella G. Filbin, D. Cahill, T. Juratli, 2017, Pharmacology & therapeutics.

Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications

D. Cahill, H. Shih, O. Andronesi, 2017, Cancer.

Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations

D. Cahill, I. McCutcheon, T. Juratli, 2015, Expert review of anticancer therapy.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

M. Weller, D. Cahill, K. Plate, 2018, Nature Medicine.

Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma.

T. Mikkelsen, A. Iafrate, P. Wen, 2020, JCO precision oncology.

Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.

K. Aldape, D. Cahill, G. Fuller, 2012, Annals of diagnostic pathology.

Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.

K. Aldape, D. Cahill, G. Fuller, 2012, Annals of diagnostic pathology.

Sirtuin activation targets IDH-mutant tumors.

H. Wakimoto, D. Cahill, Julie J. Miller, 2020, Neuro-oncology.

Extreme Vulnerability of ID H 1 Mutant Cancers to NAD + Depletion Graphical Abstract Highlights

A. Iafrate, K. Flaherty, H. Wakimoto, 2022 .

IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy.

H. Wakimoto, D. Cahill, K. Tateishi, 2017, Neurosurgery.

Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.

Kyle R. Noll, D. Cahill, G. Rao, 2016, Neuro-oncology.

Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.

D. Louis, D. Cahill, J. Cairncross, 2015, CNS oncology.

TargetableSignalingPathwayMutationsAreAssociatedwith Malignant Phenotype in IDH-Mutant Gliomas

A. Iafrate, H. Wakimoto, D. Cahill, 2014 .

Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.

Jennie W. Taylor, D. Cahill, A. Chi, 2013, Oncology.

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts

M. Marra, W. Mason, J. Cairncross, 2018, PloS one.

Genetic instability and darwinian selection in tumours.

K. Kinzler, B. Vogelstein, D. Cahill, 1999, Trends in cell biology.

The Molecular Basis of Chromosomal Instability in Human Cancer Cells

D. Cahill, 2003 .

Glioma-Associated Cytomegalovirus Mediates Subversion of the Monocyte Lineage to a Tumor Propagating Phenotype

Nicholas B. Levine, D. Cahill, G. Rao, 2011, Clinical Cancer Research.

MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

Stephen Yip, David N. Louis, A. John Iafrate, 2009, Clinical Cancer Research.

Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment

P. A. Futreal, M. Stratton, A. Iafrate, 2007, Clinical Cancer Research.

Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair

H. Wakimoto, D. Cahill, Jianfang Ning, 2020, Clinical Cancer Research.

Carcinogen-specific induction of genetic instability

K. Kinzler, B. Vogelstein, D. Cahill, 2001, Proceedings of the National Academy of Sciences of the United States of America.

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma

A. Iafrate, D. Louis, D. Cahill, 2019, Acta Neuropathologica Communications.

Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases

Brian L. Shaw, S. Carter, S. Prakadan, 2021, Nature Communications.

TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas

Hakho Lee, C. Bettegowda, D. Cahill, 2020, Clinical Cancer Research.

Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma

Jennie W. Taylor, P. Wen, D. Cahill, 2014, Journal of Neuro-Oncology.

Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas

D. Cahill, M. Frosch, P. Brastianos, 2019, Journal of Neurological Surgery Part B: Skull Base.

Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.

D. Cahill, M. Frosch, P. Brastianos, 2017, Journal of neurosurgery.

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.

D. Louis, R. Sullivan, Dennie T. Frederick, 2016, Journal of the National Cancer Institute.

Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features

H. Wakimoto, D. Cahill, P. Brastianos, 2020, Acta Neuropathologica.

TERT and DNMT1 expression predict sensitivity to decitabine in gliomas.

D. Cahill, M. Monje, W. Wick, 2020, Neuro-oncology.

Updates in prognostic markers for gliomas.

D. Cahill, P. Brastianos, E. Aquilanti, 2018, Neuro-oncology.

Characterization of MAD2B and other mitotic spindle checkpoint genes.

K. Kinzler, B. Vogelstein, D. Cahill, 1999, Genomics.

A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma

Y. Fujii, H. Wakimoto, D. Cahill, 2020, Cancer Research.

Isocitrate Dehydrogenase Mutations in Low-Grade Gliomas Correlate With Prolonged Overall Survival in Older Patients

D. Cahill, W. Curry, M. Frosch, 2019, Neurosurgery.

Genotype-targeted local therapy of glioma

Ameya R. Kirtane, Julie M. Batten, M. Meyerson, 2018, Proceedings of the National Academy of Sciences.

IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice

Linda T. Nieman, H. Wakimoto, D. Cahill, 2020, Oncoimmunology.

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.

A. Iafrate, D. Cahill, B. Nahed, 2016, The oncologist.

3 Tesla intraoperative MRI for brain tumor surgery

J. Madsen, D. Cahill, W. Curry, 2014, Journal of magnetic resonance imaging : JMRI.

TERT Alterations in Progressive Treatment-Resistant Meningiomas.

D. Cahill, P. Brastianos, T. Juratli, 2018, Neurosurgery.

Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas

A. Giobbie-Hurder, D. Cahill, W. Curry, 2022, Nature Communications.

Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid

Brian L. Shaw, A. Giobbie-Hurder, S. Carter, 2021, JAMA network open.

Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes.

S. Hilsenbeck, R. Schiff, Y. Nikolsky, 2016, Cancer research.

Treatment of brain metastases in the modern genomic era

D. Cahill, P. Brastianos, S. Santagata, 2017, Pharmacology & therapeutics.

Systemic Therapy of Brain Metastases

D. Cahill, P. Brastianos, H. Brastianos, 2014, Current Neurology and Neuroscience Reports.

MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.

D. Louis, D. Cahill, W. Curry, 2008, Clinical neurosurgery.

Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations

A. Giobbie-Hurder, S. Carter, A. Iafrate, 2021, Nature Cancer.

A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma

H. Wakimoto, D. Cahill, R. Martuza, 2019, Targeted oncology.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Sean P. Brown, C. Azzoli, D. Cahill, 2018, Cancer discovery.

DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome

Julie M. Batten, S. Carter, A. Iafrate, 2018, Acta Neuropathologica.

Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.

A. Iafrate, D. Louis, D. Cahill, 2018, Neuro-oncology.

HSP90 inhibition overcomes resistance to molecular targeted therapy in BRAFV600E mutant high-grade glioma.

Y. Fujii, H. Wakimoto, D. Cahill, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Rapid Intraoperative Molecular Characterization of Glioma.

W. Hahn, M. Meyerson, L. Garraway, 2015, JAMA oncology.

Malignant Melanoma Metastatic to Oligodendroglioma: Case Report and Literature Review of Tumor-to-Tumor Metastasis to Gliomas.

D. Cahill, M. Frosch, M. Koch, 2018, Journal of neuropathology and experimental neurology.

Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study.

Derek H. Oakley, D. Cahill, M. Frosch, 2018, The oncologist.

The role of neuropathology in the management of patients with diffuse low grade glioma

J. Olson, K. Aldape, D. Louis, 2015, Journal of Neuro-Oncology.

Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th annual Frye-Halloran Brain Tumor Symposium.

D. Cahill, W. Curry, G. Dunn, 2013, Neurosurgical focus.

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor

A. Iafrate, D. Cahill, P. Brastianos, 2017, npj Precision Oncology.

Neurosurgical involvement in clinical trials for CNS tumors

D. Cahill, M. Vogelbaum, J. Elder, 2021, Journal of Neuro-Oncology.

Extent of Resection of Glioblastoma: A Critical Evaluation in the Molecular Era.

D. Cahill, 2021, Neurosurgery clinics of North America.

Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma.

D. Louis, D. Cahill, A. Chi, 2016, The New England journal of medicine.

The role of biopsy in the management of patients with presumed diffuse low grade glioma

J. Olson, T. Ryken, D. Cahill, 2015, Journal of Neuro-Oncology.

Rapid IntraoperativeMolecular Characterization of Glioma

W. Hahn, L. Garraway, P. Wen, 2015 .

Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing

Betty Y. S. Kim, K. Aldape, M. Gilbert, 2014, Journal of Neuro-Oncology.

Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.

Susan M. Chang, M. Berger, D. Brat, 2014, Neuro-Oncology.

PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency–Mediated Acquired Resistance to Temozolomide

H. Wakimoto, D. Cahill, Julie J. Miller, 2018, Molecular Cancer Therapeutics.

Prospective Randomized Trial of Post-operative Stereotactic Radiosurgery versus Observation for Completely Resected Brain Metastases

Nicholas B. Levine, P. Brown, K. Hess, 2017, The Lancet. Oncology.

Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.

Nicholas B. Levine, P. Brown, K. Hess, 2017, The Lancet. Oncology.

Perspectives on investigational drugs and immunotherapies for glioblastoma

D. Cahill, W. Curry, Julie J. Miller, 2016, Expert opinion on investigational drugs.

Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series.

K. Flaherty, D. Cahill, W. Curry, 2015, Neurosurgical focus.

Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study

David W. Roberts, Oren Sagher, Theodore H. Schwartz, 2016, Neurosurgery.

Butterfly glioblastomas: a retrospective review and qualitative assessment of outcomes

Sujit S. Prabhu, Nicholas B. Levine, Dima Suki, 2012, Journal of Neuro-Oncology.

Impact of Intraoperative Magnetic Resonance Imaging and Other Factors on Surgical Outcomes for Newly Diagnosed Grade II Astrocytomas and Oligodendrogliomas: A Multicenter Study.

Steven R. Abram, G. Sutherland, M. Smyth, 2020, Neurosurgery.

In Vivo Absolute Metabolite Quantification Using a Multiplexed ERETIC‐RX Array Coil for Whole‐Brain MR Spectroscopic Imaging

L. Wald, D. Cahill, B. Keil, 2021, Journal of magnetic resonance imaging : JMRI.

Improving D‐2‐hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RF‐receive/B0‐shim array coils at 3 T

B. Gagoski, E. Adalsteinsson, D. Cahill, 2021, NMR in biomedicine.

'Real world' use of a highly reliable imaging sign: 'T2-FLAIR mismatch' for identification of IDH mutant astrocytomas.

Sohil H. Patel, M. Castillo, D. Cahill, 2020, Neuro-oncology.

Evidence-based recommendations on categories for extent of resection in diffuse glioma.

M. Berger, M. J. van den Bent, M. Weller, 2021, European journal of cancer.

Glioblastoma care in the elderly

D. Cahill, T. Batchelor, E. Gerstner, 2016, Cancer.

Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups

D. Cahill, G. Schackert, Julie J. Miller, 2018, Journal of Neuro-Oncology.

Intracranial neoplasms can arise from any of the structures or cell types present in the cranial vault, including the brain, meninges, pituitary gland, skull, and even residual embryonic tissue.

D. Cahill, J. Loeffler, N. Shonka, 2015 .

Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma

Nicholas D. Camarda, S. Carter, A. Iafrate, 2020, Nature Genetics.

Immunohistochemical detection of somatostatin receptor subtype 5 (SSTR-5) in cushing adenoma

Nicholas B. Levine, D. Cahill, G. Fuller, 2010, Journal of Neuro-Oncology.

BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.

P. Brown, A. Iafrate, D. Cahill, 2021, The New England journal of medicine.

Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.

D. Cahill, P. Brastianos, S. Santagata, 2016, Neurosurgical focus.

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.

Raymond Y Huang, Susan M. Chang, M. Berger, 2022, Neuro-oncology.

In Reply: A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas

D. Cahill, P. Brastianos, F. Barker, 2019, Neurosurgery.

TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations

A. Iafrate, D. Cahill, Julie J. Miller, 2018, Acta Neuropathologica Communications.

EXTH-42. H3 K27M MUTANT GLIOMAS ARE SELECTIVELY KILLED BY ONC201, A SMALL MOLECULE INHIBITOR OF DOPAMINE RECEPTOR D2

P. Wen, H. Wakimoto, D. Cahill, 2017 .

Author Correction: Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases

Brian L. Shaw, S. Carter, S. Prakadan, 2021, Nature Communications.

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

Brian L. Shaw, A. Giobbie-Hurder, R. Sullivan, 2020, Nature Network Boston.

Neural encoding and production of functional morphemes in the posterior temporal lobe

Mirela V. Simon, Evelina Fedorenko, Daniel K Lee, 2018, Nature Communications.

Management of brain metastases in the era of targeted and immunomodulatory therapies.

D. Cahill, P. Brastianos, 2015, Oncology.

Phase II study of pembrolizumab in leptomeningeal carcinomatosis.

A. Giobbie-Hurder, S. Carter, S. Prakadan, 2018 .

Inductively Coupled, Transmit-Receive Coils for Proton MRI and X-nucleus MRI/MRS in Small Animals

Y. Yen, H. Wakimoto, D. Cahill, 2023, Journal of Magnetic Resonance Open.

Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment

R. Jain, A. Sorensen, D. Cahill, 2008 .

Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results

A. Giobbie-Hurder, P. Wen, D. Cahill, 2023, Nature Medicine.

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

B. Rosen, A. Iafrate, P. Wen, 2018, Nature Communications.

Microenvironmental landscape of human melanoma brain metastases in response to immune checkpoint inhibition.

McKenzie L. Shaw, Brian L. Shaw, S. Carter, 2022, Cancer immunology research.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma

Matthew J. Frigault, H. Wakimoto, D. Cahill, 2022, Neuro-oncology advances.

Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy

Maristela L Onozato, A. Iafrate, H. Wakimoto, 2019, Scientific Reports.

Receptor tyrosine kinase gene amplification is predictive of intraoperative seizures during glioma resection with functional mapping.

Mirela V. Simon, D. Cahill, B. Nahed, 2020, Journal of neurosurgery.

Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine.

Susan M. Chang, K. Aldape, M. Mehta, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Intraoperative thalamocortical tract monitoring via direct cortical recordings during craniotomy

Mirela V. Simon, Athar N. Malik, D. Cahill, 2021, Clinical Neurophysiology.

Abstract 5270: IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas

K. Aldape, M. Gilbert, D. Cahill, 2015 .

Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide

Lynette M. Smith, M. Gilbert, D. Cahill, 2013, Journal of Neuro-Oncology.

Patel glioblastoma Single-cell RNA-seq highlights intratumoral heterogeneity in primary

Shawn M. Gillespie, A. Regev, D. Louis, 2014 .

TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations

A. Iafrate, D. Cahill, Julie J. Miller, 2018, Acta neuropathologica communications.

2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets

W. Hahn, G. Getz, R. Beroukhim, 2015 .